Investment
Features
FeesSafety
Academy
More
Pluang+

FB Financial sees growth in deposits, loans, and net interest margin, maintaining a soft Buy rating despite credit concerns.

Analyst Insights
28 Sep 2026
Seeking Alpha
View Source
Bullish
FB Financial sees growth in deposits, loans, and net interest margin, maintaining a soft Buy rating despite credit concerns.

FB Financial Corporation continues to show strong balance sheet growth with increasing deposits and loans, alongside a rising net interest margin now at 3.95%, outperforming many peers. The bank maintains solid asset quality and a return on assets of 1.44%, though non-performing loans are slightly above preferred levels and require monitoring. Despite a somewhat high valuation and credit quality concerns, rising interest rates are expected to modestly improve FB Financial's profitability, supporting a soft Buy rating from analysts.

As of Sep 29, 2026 02:52 WIB, FB Financial Corporation is noted here with a snapshot of the Financials sector on Pluang. For readers following Financials, here is Pluang's market snapshot as of Sep 29, 2026 02:52 WIB: out of 85 priced Financials-sector US stocks, 8 rose and 76 fell today. Notable movers include AVAT at USD 1.67 with a 1-day change of -11.41%, NU at USD 12.26 with a 1-day change of -9.79%, and GEMI at USD 5.20 with a 1-day change of -6.14%.

More News

Several high-volume stocks plunge sharply amid profit-taking despite positive updates.

Several high-volume stocks plunge sharply amid profit-taking despite positive updates.

Several high-volume stocks including ITG Inc, Adicet Bio, Jaguar Health, Ocular Therapeutix, and Greenland Mines experienced sharp declines despite recent positive company news. The drops, ranging from about 19% to over 32%, appear driven by profit-t...

Market News
Bearish
2 hours ago
Stocks jump on clinical trial updates, acquisition deals, and trading momentum.

Stocks jump on clinical trial updates, acquisition deals, and trading momentum.

Kodiak Sciences surged 178% following positive Phase III trial updates for a wet age-related macular degeneration treatment. Lifecore Biomedical rose 55% after agreeing to a $663.7 million acquisition by Webster Equity Partners. YD Bio gained 22%, li...

Market News
Bullish
2 hours ago
Lifecore Biomedical shares jump 55% on acquisition news, analyst downgrades to Hold.

Lifecore Biomedical shares jump 55% on acquisition news, analyst downgrades to Hold.

Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...

Market News
Bullish
3 hours ago
Espey director sells shares amid stock valued 112% above fair value despite strong earnings.

Espey director sells shares amid stock valued 112% above fair value despite strong earnings.

A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...

Market News
Neutral
3 hours ago
Vail Resorts beats Q4 revenue estimates, targets $106M in cost savings for profit boost

Vail Resorts beats Q4 revenue estimates, targets $106M in cost savings for profit boost

Vail Resorts reported Q4 earnings per share of -$5.34, slightly better than expected, with revenue of $278.1 million surpassing estimates. The company benefited from a 5.2% rise in mountain revenues, driven by strong pass sales in Australia and stabl...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App